Investing Investment Analysts

More

China Slowdown Hitting the High-End?

A slower economy in China is hitting high-end retailers, like Burberry. Bryan Gildenberg, Kantar retail analyst, explains the tough situation luxury retailers are facing.

The China Effect on High-End Retail

The economic slowdown in China is impacting Burberry sales, reports CNBC's Courtney Reagan. Stacey Widlitz of SW Retail Advisors, and Erika Maschmeyer of R.W. Baird, provide perspective.

FMHR Top Three Trades

The FMHR traders weigh in with their top three stock plays. Steve Milunovich, UBS analyst, discusses the direction of IBM's earnings and explains why he has a "buy" rating on Apple and considers the stock "cheap" at these levels.

Yahoo on the Search for a New CEO

Jordan Rohan, Stifel Nicolaus senior analyst, discusses Yahoo's efforts to find a new top executive, and explains why he thinks Ross Levinsohn is the top contender for the spot, and has set a price target of $21 a share on the stock.

Weak Demand Hits Chip Outlook

Cummins plunged 9 percent today on news the company lowered its Q2 and full-year guidance today, with the FMHR traders; and Applied Micro Devices & Applied Materials both slashed their estimates yesterday, with Chris Danely, JPMorgan analyst.

Nomura Upgrades American Express

Shares of American Express jump 1 percent on the Nomura upgrade. Bill Carcache, Nomura senior payments analyst, weighs in.

Will Mini iPad Eat Android's Lunch?

Discussing Apple's debut of its smaller version of the iPad, and its impact on competitors like Amazon, with Gene Munster, Piper Jaffray analyst.

Drought Sparks Historical Commodity Rally: Expert

A look at why commodity prices are skyrocketing as a result of this summer's drought, with Jason Roose, U.S. Commodities analyst.

UBS Analyst on the Credit Card Trade

John Williams, UBS analyst, discusses his company's downgrade on Visa and MasterCard. "These are by no means broken companies, or broken stories, it's just right now we do not like the macro setup," says Williams.

Jefferies: Buy Wells Fargo

Ken Usdin, Jefferies, explains his bullish call on Wells Fargo ahead of the bank's earnings this Friday. Meanwhile Nicole Miller Regan, Piper Jaffray, says Green Mountain's "golden age" is gone.

FMHR's Final Trade

The FMHR traders share their final trades.

Navistar Plunges Nearly 16%

Navistar plunges nearly 16 percent after announcing a development strategy, with the FMHR traders and CNBC's Herb Greenberg. Meanwhile Brad Hintz, Sanford Bernstein analyst, weighs in on "mediocre" financial earnings.

Dow Has Biggest Drop Since June 21

Stocks are sliding today on a disappointing jobs number, with the Fast Money traders. Meanwhile German financial regulators are investigating Deutsche Bank in the Libor probe, with Chirantan Barua, senior analyst at Bernstein Research.

Does an iPad Mini Equal Big Opportunity?

Reports suggest Apple is moving closer to launching a smaller and cheaper tablet. Brian White, Topeka Capital Markets senior analyst, provides perspective on how this could impact its business.

Consumer Losing Steam?

Discussing China and the ECB's decision to cut bank interest rates, the dip in gold and unemployment, with Dan Greenhaus of BTIG; and Liz Dunn, Macquarie Research analyst shares her outlook on the retail sector since this morning's disappointing June same-store sales numbers.

Bove on Living Wills Report

Breaking down the bankruptcy processes and other details from the banks' "living wills," which were released by the FDIC and the Fed. With Peter Boockvar, Miller Tabak; Dick Bove, Rochdale Securities; and Larry McDonald, Wall Street insider.

Will Travel Stocks Keep on Flying?

Discussing whether internet travel stocks have more room to run, with Herman Leung, Susquehanna Financial Group.

Homebuilders Hit New 52-Week High

Nishu Sood, Deutsche Bank homebuilder analyst, weighs in on whether he thinks the latest positive homebuilder data means a housing recovery is on its way.

High-Flying Travel Stocks

Online travel names, like Priceline and Expedia, are among a few of the S&P 500's top performers for the first half of the year. Jake Fuller, Lazard Capital Markets analyst, and Andre Sequin, RBC Capital Markets analyst, weigh in. "Travel is a lagging economic indicator, not a leading one," says Fuller.

Telecom: Still the Leader?

Telecom is among the sectors surging today, and trading at levels not seen since June of 2008. Christopher King, Stifel Nicolaus, shares his opinions on where the sector is headed in the third quarter. Matt Cheslock of Virtu Financial, also weighs in on the best plays in the sector.

Making a Bull Case for RIMM: Analyst

Daniel Ernst, Hudson Square Research, explains why he upgraded the tech stock to "buy" from "hold," despite an earnings miss and plummeting sales.

Groupon Stock Tumbles

Herman Leung, Susquehanna Financial Group analyst, explains why he cut the price target from $15 to $12 for the e-commerce company.

How to Play Wal-Mart

The trade on the giant retailer and whether the company can keep its momentum going, with Deborah Weinswig, Citi retail analyst, and Robert Carroll, UBS retail analyst.

Fade This End of Quarter Bounce?

Brad Lamensdorf, The Active Bear Portfolio, provides the best "short" plays in the market.

Nike Falls After Big Earnings Miss

Sam Poser, analyst at Sterne Agee, weighs in why he downgraded Nike stock to "neutral" from "buy."

One Hour Into Trading...

Alan Knuckman, OneStopOption.com, shares his view of the markets.

ACA Impact on Election & Markets

CNBC's Jon Fortt reports on the details of Research In Motion; and Ed Mills, Financial Policy analyst, shares his opinions on the health-care ruling.

Research In Motion Plunges 17%

Nike plunges post-earnings, with the FMHR traders; and discussing whether Research In Motion can recover, with Shaw Wu, Sterne Agee analyst.

Arena Surges on FDA Approval

Shares of Arena Pharmaceuticals spiked on news the FDA approved its anti-obesity drug, with the Fast Money traders; and discussing how tomorrow's ruling on the health care reform could impact the biotech sector, with Mark Schoenebaum, ISI.

Biotech & Drug Stocks: Scotus Ruling Impact

The biotech sector is up more than 1 percent today, and discussing what investors can expect after tomorrow's health care reform ruling, with ISI's biotech and pharmaceuticals major analyst Mark Schoenebaum. "If tomorrow the whole bill is struck down, technically, earnings and revenue estimates for all of biotech and all of pharma companies are going to go up," says Schoenebaum.